JHVEPhoto/iStock Editorial via Getty Images Sanofi ( NASDAQ: SNY ) said that development of SAR442501, currently in phase 2 to treat pediatric patients with achondroplasia, the genetic disorder that causes dwarfism, will likely come to an end. The French pharma said that the ongoing phase 2 trial will continue "but is not expected to advance further." In its Q2 financial results news release , Sanofi ( SNY ) said it will also end development of riliprubart but just in the rare autoimmune disorder cold agglutinin disease.
It is currently in phase 2 for that indication, but development will continue in chronic inflammatory demyelinating polyneuropathy. More on Sanofi Sanofi (SNY) Q2 2024 Earnings Call Transcript Sanofi 2024 Q2 - Results - Earnings Call Presentation Sanofi's Immunology Business Is Doing A Lot Of Heavy Lifting Sanofi Non-GAAP EPS of €1.73, revenue of €10.
74B; raises FY24 EPS outlook Kymera announces expansion of KT-474 HS and AD phase 2 studies.
